Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, Minsuk Kwon
Received February 3, 2024 Accepted September 12, 2024 Published online September 19, 2024
Purpose Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the medical potential of WGS.
Materials and Methods This study evaluates target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. Forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches.
Results TE-WGS detected all variants reported by TSO500 (100%, 498/498). A high correlation in variant allele fractions was observed between TE-WGS and TSO500 (r=0.978). Notably, 223 variants (44.8%) within the common set were discerned exclusively by TE-WGS in peripheral blood, suggesting their germline origin. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion genes, microsatellite instability, and homologous recombination deficiency scores, which were essential for clinical decision-making.
Conclusion TE-WGS is a comprehensive approach in personalized oncology, matching TSO500’s key biomarker detection capabilities. It uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.
Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641. Published online December 5, 2023
Purpose In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.
Citations
Citations to this article as recorded by
ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock Materials Today Bio.2025; 30: 101424. CrossRef
Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh
Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023
Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.
Citations
Citations to this article as recorded by
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho BJUI Compass.2024; 5(3): 327. CrossRef
Dong Wook Shin, Sang Hyub Lee, Tae-Hwan Kim, Seok Joong Yun, Jong Kil Nam, Seung Hyun Jeon, Seung Chol Park, Seung Il Jung, Jong-Hyock Park, Jinsung Park
Cancer Res Treat. 2019;51(2):556-567. Published online July 16, 2018
Purpose
Health-related quality of life (HRQOL) information related to radical prostatectomy (RP) is valuable for prostate cancer (PC) patients needing to make treatment decisions. We aimed to investigate HRQOL change in PC patients who underwent three types of RP (open, laparoscopic, or robotic) and compared their HRQOL with that of general population.
Materials and Methods
Patients were prospectively recruited between October 2014 and December 2015. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) and PC-specific module (PR25) were administered before surgery (baseline) and at postoperative 3 and 12 months. At each time point, HRQOL was compared, and a difference of 10 out of 0-100 scale was considered clinically significant.
Results
Among 258 screened patients, 209 (41 open, 63 laparoscopic, and 105 robotic surgeries) were included. Compared to baseline, physical, emotional, and cognitive functioning improved at 12 months. Role functioning worsened at 3 months, but recovered to baseline at 12 months. Pain, insomnia, diarrhea, and financial difficulties also significantly improved at 12 months. Most PR25 scales excluding bowel symptoms deteriorated at 3 months. Urinary symptoms and incontinence aid recovered at 12 months, whereas sexual activity and sexual function remained poor at 12 months. Clinically meaningful differences in HRQOL were not observed according to RP modalities. Compared to the general population, physical and role functioning were significantly lower at 3 months, but recovered by 12 months. Social functioning did not recover.
Conclusion
Most HRQOL domains showed recovery within 12 months after RP, excluding sexual functioning and social functioning. Our findings may guide patients considering surgical treatment for PC.
Citations
Citations to this article as recorded by
Quality of life after robotic versus conventional minimally invasive cancer surgery: a systematic review and meta-analysis Russell Seth Martins, Asad Saulat Fatimi, Omar Mahmud, Muhammad Umar Mahar, Arshia Jahangir, Kinza Jawed, Shalni Golani, Ayra Siddiqui, Syed Roohan Aamir, Ali Ahmad Journal of Robotic Surgery.2024;[Epub] CrossRef
The Effect of Discharge Education and Post-Discharge Telephone Counseling on Quality of Life in Patients Undergoing Radical Prostatectomy: A Randomized Controlled Study İpek Köse Tosunöz, Sevgi Deniz Doğan, Şeyma Yurtseven, Sevban Arslan Cukurova Anestezi ve Cerrahi Bilimler Dergisi.2024; 7(3): 205. CrossRef
Health‐related quality of life the first year after a prostate cancer diagnosis a systematic review Louise Dorner Østergaard, Mads Hvid Poulsen, Malene Eiberg Jensen, Lars Lund, Malene Grubbe Hildebrandt, Birgitte Nørgaard International Journal of Urological Nursing.2023; 17(1): 15. CrossRef
Quantitative Analysis of Quality of Life and Exploration of Influencing Factors in Patients Undergoing Radical Prostatectomy Feiyang Wang, Jiajun Chen, Weihao Wang, Mengyao Li, Chao Peng, Shouhua Pan, Chuanchuan Zhan, Keyuan Zhao, Yulei Li, Lulu Zhang, Gang Xu, Jing Jin Urology.2023; 181: 105. CrossRef
Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial Josée Savard, Hanane Moussa, Jean‐François Pelletier, Pierre Julien, Louis Lacombe, Rabi Tiguert, Yves Caumartin, Thierry Dujardin, Paul Toren, Frédéric Pouliot, Michele Lodde, Yves Fradet, Karine Robitaille, Vincent Fradet Cancer Medicine.2023; 12(19): 20163. CrossRef
Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne Cancer Management and Research.2022; Volume 14: 1525. CrossRef
A systematic review of supervised comprehensive functional physiotherapy after radical prostatectomy B. Steenstrup, M. Cartier, F.X. Nouhaud, G. Kerdelhue, M. Gilliaux Progrès en Urologie.2022; 32(7): 525. CrossRef
Perioperative psychological issues and nursing care among patients undergoing minimally invasive surgeries Kehua Yang, Xu Shao, Xinghui Lv, Feimin Yang, Qunyan Shen, Jing Fang, Wei Chen Laparoscopic, Endoscopic and Robotic Surgery.2022; 5(3): 92. CrossRef
A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association Yun-Sok Ha, Kwang Taek Kim, Wook Nam, Hongzoo Park, Sangjun Yoo, Chan Ho Lee, Ho Seok Chung, Woo Suk Choi, Jiyoun Kim, Jaeeun Shin, Jeong Hyun Kim, Cheol Kwak The Korean Journal of Urological Oncology.2022; 20(4): 265. CrossRef
Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study Myung Soo Kim, Seung Il Jung, Ho Seok Chung, Eu Chang Hwang, Dongdeuk Kwon Prostate International.2021; 9(3): 132. CrossRef
Quality of life assessment using EORTC QLQ questionnaires in the prostate cancer population treated with radical prostatectomy: a systematic review Tomasz Jurys, Jacek Durmala Scandinavian Journal of Urology.2021; 55(2): 90. CrossRef
Évaluation de l’observance et de l’adhésion thérapeutique de deux protocoles de rééducation après prostatectomie Benoit Steenstrup, Claire Breton, Guillaume Galliou, François-Xavier Nouhaud Kinésithérapie, la Revue.2021; 21(234): 12. CrossRef
Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy Yann Neuzillet, Mathieu Rouanne, Jean-François Dreyfus, Jean-Pierre Raynaud, Marc Schneider, Morgan Roupret, Sarah Drouin, Marc Galiano, Xavier Cathelinau, Thierry Lebret, Henry Botto Asian Journal of Andrology.2021; 23(4): 370. CrossRef
The Effect of Post-prostatectomy Urinary Incontinence on Health-related Quality of Life in Patients with Prostate Cancer Jeong Hyun Kim, Yeon Soo Jang, Young Deuk Choi, Eui Geum Oh Korean Journal of Adult Nursing.2019; 31(3): 293. CrossRef
Prostate-specific health-related quality of life and patient-physician communication — A 3.5-year follow-up Nicole Ernstmann, Jan Herden, Lothar Weissbach, André Karger, Kira Hower, Lena Ansmann Patient Education and Counseling.2019; 102(11): 2114. CrossRef
Purpose
We aimed to evaluate psychometric properties of the Korean version of the EORTC QLQ-NMIBC24 when applied to Korean non-muscle invasive bladder cancer (NMIBC) patients.
Materials and Methods
A total of 249 patients who underwent curative transurethral resection of bladder tumor (TURBT) for primary orrecurrentNMIBCwere asked to complete theKorean version of EORTC QLQ-C30 and -NMIBC24 questionnaires three times (preoperative, post-TURBT 3 months and 6 months). Linguistic validation and psychometric evaluation of the questionnaire was conducted.
Results
Multitrait scaling analysis confirmed satisfactory construct validity in five scales except the malaise scale. Internal consistency was good (Cronbach’s alpha ≥ 0.70) for the five scales except the malaise scale at the all three time points. Known-group comparison analyses showed better quality-of-life (QOL) scores in patients with higher performance status as expected, and better sexual function in men than women (p < 0.05). Most of the scales had low correlations (< 0.40) with the scales in QLQ-C30 showing divergent validity, except for malaise scale which showed higher correlations (0.42 to 0.60). Responsiveness to change was consistent with clinical implications over time after TURBT.
Conclusion
The Korean version of the EORTC QLQ-NMIBC24 has good reliability and cross-cultural validity for measuring various QOL aspects that can be self-administered to Korean NMIBC patients undergoing TURBT.
Citations
Citations to this article as recorded by
Health-related Quality of Life During the First 4 Years After Non–Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort Ivy Beeren, Nena E. Klerks, Katja K. Aben, Jorg R. Oddens, J. Alfred Witjes, Lambertus A. Kiemeney, Alina Vrieling European Urology Oncology.2024; 7(4): 829. CrossRef
The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review E. Rammant, L. Fox, K. Beyer, N. K. Aaronson, R. Chaloner, S. De Padova, F. Liedberg, L. M. Wintner, K. Decaestecker, V. Fonteyne, N. Perdek, H. Wylie, J. W. F. Catto, T. M. Ripping, B. Holzner, M. Van Leeuwen, M. Van Hemelrijck Quality of Life Research.2023; 32(8): 2127. CrossRef
Quality of life in bladder cancer: systematic review and meta-analysis Sima Rafiei, Golnaz Kheradkhah, Grigorios Kotronoulas, Maryam Doustmehraban, Farnoosh Shafiei, Maryam Masoumi, Elaheh Parnian, Elmira Nosrati Sanjabad, Ahmad Ghashghaee BMJ Supportive & Palliative Care.2023; 13(e3): e707. CrossRef
Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis Jeongok Park, Young Deuk Choi, Kyoungjin Lee, Miae Seo, Ahyoung Cho, Sejeong Lee, Keum-hee Nam Asia-Pacific Journal of Oncology Nursing.2022; 9(6): 100063. CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer T. M. Ripping, E. Rammant, J. A. Witjes, N. K. Aaronson, M. van Hemelrijck, L. M. C. van Hoogstraten, J. Boormans, C. A. Goossens, A. G. van der Heijden, M. C. C. M. Hulshof, G. J. L. H. van Leenders, A. M. van Leliveld, R. P. Meijer, R. J. A. van Moorsel Health and Quality of Life Outcomes.2022;[Epub] CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer Theodora M. Ripping, Ellen Westhoff, Neil K. Aaronson, Mieke Van Hemelrijck, Elke Rammant, J. Alfred Witjes, Lambertus. A. Kiemeney, Katja K. H. Aben, Alina Vrieling Journal of Patient-Reported Outcomes.2021;[Epub] CrossRef
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews
Lauren J Lee, Christina S Kwon, Anna Forsythe, Carla M Mamolo, Elizabeth T Masters, Ira A Jacobs ClinicoEconomics and Outcomes Research.2020; Volume 12: 693. CrossRef
Effect of a patient education and rehabilitation program on anxiety, depression and quality of life in muscle invasive bladder cancer patients treated with adjuvant chemotherapy Zhonghui Li, Dan Wei, Chenxi Zhu, Qing Zhang Medicine.2019; 98(44): e17437. CrossRef